Physician profile
Stephen Lapin
NPI 1073567376
$19,243.96
in general payments reported to CMS, 2019-2025
63 companies · $8,100 in 2025
The $8,100 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,494 · 2020: $794 · 2021: $951 · 2022: $2,180 · 2023: $2,216 · 2024: $2,508 · 2025: $8,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,662 · Long Term Medical Supply Or Device Loan: $5,143 · Entertainment: $18.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,661.90 |
| Long Term Medical Supply Or Device Loan | $5,142.85 |
| Entertainment | $18.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hmu Consumables, LLC | $5,142.85 | 2025 | Dornier Medtech |
| Boston Scientific Corporation | $1,516.35 | 2019-2025 | Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $1,237.72 | 2019-2025 | Xtandi, Myrbetriq, Padcev |
| Janssen Biotech, INC. | $911.45 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $899.38 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $893.28 | 2019-2025 | |
| Pfizer INC. | $864.30 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $851.82 | 2020-2025 | Prolaris |
| Ferring Pharmaceuticals INC. | $747.27 | 2019-2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $593.77 | 2021-2025 | Pylarify |
| Antares Pharma, INC. | $502.97 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $425.20 | 2019-2025 | |
| Allergan, INC. | $300.25 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $297.38 | 2019-2023 | Aveed, Xiaflex |
| Endo USA, INC. | $292.84 | 2024-2025 | Aveed, Xiaflex |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $282.84 | 2019-2024 | Prolia |
| Dendreon Pharmaceuticals LLC | $275.83 | 2019-2025 | Provenge |
| Myovant Sciences INC. | $217.46 | 2021-2022 | |
| Convatec INC. | $197.92 | 2022-2023 | |
| Urogen Pharma, INC. | $196.83 | 2021-2024 | Jelmyto |
| Biotissue Holdings INC. | $196.79 | 2022-2025 | |
| Urovant Sciences INC | $183.99 | 2021-2022 | |
| Coloplast Corp | $161.66 | 2019-2023 | Altis |
| Procept Biorobotics Corporation | $151.60 | 2024-2025 | Aquabeam System |
| Astrazeneca Pharmaceuticals Lp | $147.92 | 2021-2022 | |
| Ambu INC. | $123.64 | 2021-2024 | |
| Blue Earth Diagnostics | $120.83 | 2021-2025 | Posluma |
| Axonics, INC. | $120.17 | 2020-2024 | Axonics |
| Medtronic, INC. | $111.55 | 2024-2025 | Interstim |
| Angiodynamics, INC. | $98.61 | 2023-2024 | Nanoknife |
| Immunitybio, INC. | $88.97 | 2024-2025 | |
| Tolmar, INC. | $84.52 | 2024-2025 | Jatenzo, Eligard |
| Merck Sharp & Dohme LLC | $80.75 | 2020-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $74.96 | 2025 | |
| Baxter Healthcare | $61.09 | 2024 | Perclot |
| Halozyme INC | $58.94 | 2023 | |
| Genzyme Corporation | $50.59 | 2021-2022 | |
| Healthtronics Stone Solutions, LLC | $48.54 | 2024 | Dornier Medtech |
| Stryker Corporation | $48.17 | 2025 | 1788 |
| Olympus America INC. | $40.04 | 2019-2024 | Itind System |
| Avanos Medical | $37.84 | 2024 | On-Q* Pump and Accessories |
| Pacira Pharmaceuticals Incorporated | $37.38 | 2025 | Exparel |
| Alexion Pharmaceuticals, INC. | $32.48 | 2022 | |
| Acerus Pharmaceuticals Corporation | $28.88 | 2020 | |
| Teleflex LLC | $26.66 | 2023 | Urolift |
| Sun Pharmaceutical Industries INC. | $26.59 | 2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $26.13 | 2019 | |
| 180 Medical, INC. | $24.68 | 2022 | |
| Accord Healthcare, INC. | $24.11 | 2023 | |
| Alnylam Pharmaceuticals INC. | $24.11 | 2025 | Oxlumo |
| Therapeuticsmd, INC. | $23.71 | 2019 | |
| Caris Mpi, INC. | $23.55 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $23.13 | 2025 | |
| Verity Pharmaceuticals INC. | $21.74 | 2024 | Trelstar |
| Janssen Pharmaceuticals, INC | $20.14 | 2019 | |
| Rgh Enterprises LLC | $19.21 | 2019 | |
| Provepharm INC. | $18.94 | 2024 | Bludigo |
| Dentsply Ih INC. | $18.88 | 2020 | |
| Abbott Laboratories | $18.82 | 2019 | |
| Travere Therapeutics, INC. | $18.58 | 2019 | |
| Integra Lifesciences Corporation | $16.04 | 2025 | Cytal |
| Millicent US INC | $15.99 | 2024 | Femring, Intrarosa |
| Azurity Pharmaceuticals, INC. | $15.33 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,814.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lapin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.